Activities of NXL104 combinations with ceftazidime and aztreonam against carbapenemase-Producing Enterobacteriaceae
about
"Stormy waters ahead": global emergence of carbapenemasesEmpiric therapy for hospital-acquired, Gram-negative complicated intra-abdominal infection and complicated urinary tract infections: a systematic literature review of current and emerging treatment options10 x '20 Progress--development of new drugs active against gram-negative bacilli: an update from the Infectious Diseases Society of AmericaKinetics of avibactam inhibition against Class A, C, and D β-lactamasesNew β-Lactamase Inhibitors in the ClinicImpact of the New Delhi metallo-beta-lactamase on beta-lactam antibioticsThe β-Lactams Strike Back: Ceftazidime-AvibactamHealthcare-associated infections, infection control and the potential of new antibiotics in development in the USAOP0595, a new diazabicyclooctane: mode of action as a serine β-lactamase inhibitor, antibiotic and β-lactam 'enhancer'Ceftolozane/tazobactam and ceftazidime/avibactam for the treatment of complicated intra-abdominal infectionsTargeting Antibiotic ResistanceClinical management of infections caused by multidrug-resistant EnterobacteriaceaeClass D β-lactamases: a reappraisal after five decadesAn Automated Miniaturized Method to Perform and Analyze Antimicrobial Drug Synergy AssaysNew β-lactamase inhibitors: a therapeutic renaissance in an MDR world.Discovery research: the scientific challenge of finding new antibiotics.Reclaiming the efficacy of β-lactam-β-lactamase inhibitor combinations: avibactam restores the susceptibility of CMY-2-producing Escherichia coli to ceftazidime.Ceftazidime-avibactam: a novel cephalosporin/β-lactamase inhibitor combination.Investigational antimicrobial agents of 2013.Antibiotic adjuvants: diverse strategies for controlling drug-resistant pathogens.Interaction of Avibactam with Class B Metallo-β-Lactamases.In vivo efficacy of humanized exposures of Ceftazidime-Avibactam in comparison with Ceftazidime against contemporary Enterobacteriaceae isolates.Unexpected in vivo activity of ceftazidime alone and in combination with avibactam against New Delhi metallo-β-lactamase-producing Enterobacteriaceae in a murine thigh infection model.Activity of NXL104 in combination with beta-lactams against genetically characterized Escherichia coli and Klebsiella pneumoniae isolates producing class A extended-spectrum beta-lactamases and class C beta-lactamases.Complex prosthetic joint infections due to carbapenemase-producing Klebsiella pneumoniae: a unique challenge in the era of untreatable infections.Activities of ceftazidime, ceftaroline, and aztreonam alone and combined with avibactam against isogenic Escherichia coli strains expressing selected single β-lactamases.Inhibition of Klebsiella β-Lactamases (SHV-1 and KPC-2) by Avibactam: A Structural Study.Enhancing the utility of existing antibiotics by targeting bacterial behaviour?New Delhi Metallo-beta lactamase-1 containing enterobacteriaceae: origin, diagnosis, treatment and public health concern.Current epidemiology and growing resistance of gram-negative pathogens.Randomized pharmacokinetic and drug-drug interaction studies of ceftazidime, avibactam, and metronidazole in healthy subjectsIn Vitro Activities of Ceftazidime-Avibactam, Aztreonam-Avibactam, and a Panel of Older and Contemporary Antimicrobial Agents against Carbapenemase-Producing Gram-Negative Bacilli.Clinical epidemiology of the global expansion of Klebsiella pneumoniae carbapenemasesComparative in vitro and in vivo efficacies of human simulated doses of ceftazidime and ceftazidime-avibactam against Pseudomonas aeruginosa.Characterization of a Carbapenem-Hydrolyzing Enzyme, PoxB, in Pseudomonas aeruginosa PAO1.Multiyear, Multinational Survey of the Incidence and Global Distribution of Metallo-β-Lactamase-Producing Enterobacteriaceae and Pseudomonas aeruginosa.Role of the Outer Membrane and Porins in Susceptibility of β-Lactamase-Producing Enterobacteriaceae to Ceftazidime-AvibactamSingle- and multiple-dose study to determine the safety, tolerability, and pharmacokinetics of ceftaroline fosamil in combination with avibactam in healthy subjectsActivity of Ceftazidime-Avibactam against Extended-Spectrum- and AmpC β-Lactamase-Producing Enterobacteriaceae Collected in the INFORM Global Surveillance Study from 2012 to 2014.In Vitro Susceptibility to Ceftazidime-Avibactam of Carbapenem-Nonsusceptible Enterobacteriaceae Isolates Collected during the INFORM Global Surveillance Study (2012 to 2014).
P2860
Q21131125-C12B496A-35CA-43F6-B0CD-777A029F4A83Q21146707-FEEF6EA8-78F4-4F06-9387-07A47C6789D1Q24601746-C7833F75-254A-47CA-BCEF-9154F554E4E4Q24617763-F920D1A5-A941-4E86-9596-FDE8819F93FEQ26747150-F296EAFE-8604-43AD-B727-811450FF431BQ26783267-2ED2D1BD-4459-4344-A23A-6CB911D6811BQ26796425-1F8951F5-16F3-4C9D-9DF6-C0E45A08DCA6Q26995305-03C30735-262E-49FB-8156-2258A25A3B09Q27701037-75B6CCE4-9C74-48D5-9AC4-F3A606D400D4Q28069563-C895A46F-6745-4DFC-A098-8379507CB2B5Q28078130-12037017-5A22-4001-AF8F-666234562532Q28246841-F6BF2FFE-F069-4785-A6F0-F2E75BD3ECA8Q28295700-737F04DA-4796-4DE9-8F12-E9FEAEB41678Q30364361-4AFFC22E-53B3-4E9E-B459-E369BF439F4AQ33622976-F4E43E32-B2D0-434C-879E-DD10C293394EQ33941796-99FE5C76-C5FD-40A2-A326-BF27E2A087B9Q34058217-D35EEA00-7468-4E70-BABB-F6F928CF3307Q34325573-1DCF059A-7AE9-497F-925F-53479A52A958Q34375204-5313CE1E-755D-42BC-BDAA-DBB64904DB52Q34447679-2A30F4DE-4A6B-46CA-9FEF-7B802458E392Q34533834-7C70433E-AF30-4FE0-B1F1-1C378D9ABA57Q34596516-E4C4C29C-EB56-4803-8D8F-2A97ECD7915BQ34596918-CBCAC6F4-D6F1-4F8F-8901-61FFE2F8A960Q34932937-AA41CD8E-445C-4F8A-9229-7877216DC59BQ35106776-E8CA6E7C-0375-4769-8566-20205598B384Q35556737-C6B7F981-B736-4498-AAE7-B9A8DBE53F0FQ35764780-69891AE5-961B-4AD6-935A-EC22424FF7BAQ35853204-D7A2FDBF-6236-4508-A756-311311375A27Q35885377-F0280339-7595-4254-A8F4-8009F2639AE4Q36025192-EB19AA66-2A47-4109-B453-DCCC8E273525Q36201543-0ACB8FBF-7C13-445D-A455-8739476DF96DQ36290482-B44BF220-3C1B-4D23-A63A-DBD1104DCA7DQ36357629-E9F30F53-6108-4C57-AB33-79FB63BC72ACQ36396244-97E777F7-43D2-4ED6-A9B2-BD2B759A6E05Q36571851-B7940D82-A92D-43A6-9A56-23CCB191ECD6Q36571962-78D698BF-7DEB-4349-BA59-8CE09C2D3DC6Q36644679-0983BF45-F435-4EF0-9E4F-2A210DCF905EQ36667104-6BA6D050-BF7A-4F37-9A81-3AB9069661B5Q36887866-3B3B7DD4-A746-49B8-ABDB-89C4DEA8821CQ36888062-46412D39-2932-4108-9152-EFD46E77C391
P2860
Activities of NXL104 combinations with ceftazidime and aztreonam against carbapenemase-Producing Enterobacteriaceae
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
Activities of NXL104 combinati ...... e-Producing Enterobacteriaceae
@en
type
label
Activities of NXL104 combinati ...... e-Producing Enterobacteriaceae
@en
prefLabel
Activities of NXL104 combinati ...... e-Producing Enterobacteriaceae
@en
P2093
P2860
P356
P1476
Activities of NXL104 combinati ...... e-Producing Enterobacteriaceae
@en
P2093
David M Livermore
Jiancheng Zhang
Marina Warner
Michel Doumith
Shazad Mushtaq
Sunil Maharjan
P2860
P304
P356
10.1128/AAC.00756-10
P407
P577
2010-11-01T00:00:00Z